MeiraGTx (MGTX) Competitors $8.62 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$8.62 0.00 (0.00%) As of 04:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock MGTX vs. IBRX, GMTX, ARWR, APLS, TWST, NAMS, APGE, RXRX, DNLI, and INDVShould you be buying MeiraGTx stock or one of its competitors? The main competitors of MeiraGTx include ImmunityBio (IBRX), Gemini Therapeutics (GMTX), Arrowhead Pharmaceuticals (ARWR), Apellis Pharmaceuticals (APLS), Twist Bioscience (TWST), NewAmsterdam Pharma (NAMS), Apogee Therapeutics (APGE), Recursion Pharmaceuticals (RXRX), Denali Therapeutics (DNLI), and Indivior (INDV). These companies are all part of the "pharmaceutical products" industry. MeiraGTx vs. Its Competitors ImmunityBio Gemini Therapeutics Arrowhead Pharmaceuticals Apellis Pharmaceuticals Twist Bioscience NewAmsterdam Pharma Apogee Therapeutics Recursion Pharmaceuticals Denali Therapeutics Indivior MeiraGTx (NASDAQ:MGTX) and ImmunityBio (NASDAQ:IBRX) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, risk, dividends, profitability, analyst recommendations, earnings and valuation. Is MGTX or IBRX more profitable? MeiraGTx has a net margin of -484.90% compared to ImmunityBio's net margin of -1,310.30%. ImmunityBio's return on equity of 0.00% beat MeiraGTx's return on equity.Company Net Margins Return on Equity Return on Assets MeiraGTx-484.90% -241.05% -62.93% ImmunityBio -1,310.30%N/A -121.88% Does the media refer more to MGTX or IBRX? In the previous week, MeiraGTx and MeiraGTx both had 1 articles in the media. ImmunityBio's average media sentiment score of 0.88 beat MeiraGTx's score of 0.74 indicating that ImmunityBio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MeiraGTx 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ImmunityBio 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk & volatility, MGTX or IBRX? MeiraGTx has a beta of 1.24, meaning that its share price is 24% more volatile than the S&P 500. Comparatively, ImmunityBio has a beta of 0.08, meaning that its share price is 92% less volatile than the S&P 500. Do analysts rate MGTX or IBRX? MeiraGTx presently has a consensus price target of $24.00, suggesting a potential upside of 178.42%. ImmunityBio has a consensus price target of $12.25, suggesting a potential upside of 345.45%. Given ImmunityBio's stronger consensus rating and higher possible upside, analysts plainly believe ImmunityBio is more favorable than MeiraGTx.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MeiraGTx 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00ImmunityBio 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20 Do institutionals & insiders hold more shares of MGTX or IBRX? 67.5% of MeiraGTx shares are owned by institutional investors. Comparatively, 8.6% of ImmunityBio shares are owned by institutional investors. 7.5% of MeiraGTx shares are owned by company insiders. Comparatively, 76.8% of ImmunityBio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Which has stronger valuation & earnings, MGTX or IBRX? MeiraGTx has higher revenue and earnings than ImmunityBio. ImmunityBio is trading at a lower price-to-earnings ratio than MeiraGTx, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMeiraGTx$33.28M20.81-$147.79M-$2.32-3.72ImmunityBio$14.74M164.67-$413.56M-$0.58-4.74 SummaryImmunityBio beats MeiraGTx on 9 of the 16 factors compared between the two stocks. Get MeiraGTx News Delivered to You Automatically Sign up to receive the latest news and ratings for MGTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MGTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MGTX vs. The Competition Export to ExcelMetricMeiraGTxMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$692.75M$2.96B$5.54B$9.41BDividend YieldN/A2.46%3.75%4.03%P/E Ratio-3.728.2821.0120.09Price / Sales20.81303.17433.8199.01Price / CashN/A42.5936.1658.27Price / Book9.917.678.125.65Net Income-$147.79M-$55.28M$3.25B$257.91M7 Day Performance1.77%2.50%0.97%2.09%1 Month Performance33.02%11.70%7.36%11.13%1 Year Performance84.58%4.89%31.31%18.40% MeiraGTx Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MGTXMeiraGTx4.1746 of 5 stars$8.62flat$24.00+178.4%+72.7%$692.75M$33.28M-3.72300IBRXImmunityBio2.2868 of 5 stars$2.72flat$12.25+350.4%-53.8%$2.40B$14.74M-4.69590Gap UpGMTXGemini TherapeuticsN/A$54.75+3.0%N/A+19.7%$2.37BN/A-54.7530ARWRArrowhead Pharmaceuticals3.8607 of 5 stars$16.84+0.3%$43.71+159.6%-32.7%$2.32B$3.55M-12.03400News CoveragePositive NewsAPLSApellis Pharmaceuticals4.3305 of 5 stars$17.42-4.6%$39.79+128.4%-49.3%$2.29B$781.37M-9.73770Trending NewsAnalyst ForecastInsider TradeAnalyst RevisionTWSTTwist Bioscience4.227 of 5 stars$35.59-6.8%$50.40+41.6%-36.2%$2.29B$312.97M-10.95990News CoverageNAMSNewAmsterdam Pharma3.5952 of 5 stars$19.46-2.0%$42.89+120.4%+16.9%$2.23B$45.56M-10.354News CoverageAnalyst ForecastInsider TradeAPGEApogee Therapeutics3.0043 of 5 stars$39.24-17.3%$99.00+152.3%-20.7%$2.19BN/A-10.9091High Trading VolumeRXRXRecursion Pharmaceuticals1.1335 of 5 stars$4.93-6.5%$7.00+42.0%-33.9%$2.14B$58.84M-2.79400Gap UpHigh Trading VolumeDNLIDenali Therapeutics4.537 of 5 stars$14.25-3.0%$33.71+136.6%-36.9%$2.13B$330.53M-5.34430INDVIndivior1.3487 of 5 stars$15.55+0.9%$17.00+9.3%+50.0%$2.12B$1.17B-50.161,051Upcoming Earnings Related Companies and Tools Related Companies IBRX Competitors GMTX Competitors ARWR Competitors APLS Competitors TWST Competitors NAMS Competitors APGE Competitors RXRX Competitors DNLI Competitors INDV Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MGTX) was last updated on 7/18/2025 by MarketBeat.com Staff From Our PartnersUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredFREE BUY ALERT: These 3 tiny AI stocks could surgeWe're living in unprecedented times. Most people think it's too late to get into AI right now … That the...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MeiraGTx Holdings PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share MeiraGTx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MGTX Stock Alerts